These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 22687055)

  • 1. Deuterium labeled peptides give insights into the directionality of class III lantibiotic synthetase LabKC.
    Krawczyk B; Ensle P; Müller WM; Süssmuth RD
    J Am Chem Soc; 2012 Jun; 134(24):9922-5. PubMed ID: 22687055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Curvopeptin: a new lanthionine-containing class III lantibiotic and its co-substrate promiscuous synthetase.
    Krawczyk B; Völler GH; Völler J; Ensle P; Süssmuth RD
    Chembiochem; 2012 Sep; 13(14):2065-71. PubMed ID: 22907786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leader peptide-directed processing of labyrinthopeptin A2 precursor peptide by the modifying enzyme LabKC.
    Müller WM; Ensle P; Krawczyk B; Süssmuth RD
    Biochemistry; 2011 Oct; 50(39):8362-73. PubMed ID: 21905643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of new class III lantibiotics--erythreapeptin, avermipeptin and griseopeptin from Saccharopolyspora erythraea, Streptomyces avermitilis and Streptomyces griseus demonstrates stepwise N-terminal leader processing.
    Völler GH; Krawczyk JM; Pesic A; Krawczyk B; Nachtigall J; Süssmuth RD
    Chembiochem; 2012 May; 13(8):1174-83. PubMed ID: 22556031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The leader peptide of mutacin 1140 has distinct structural components compared to related class I lantibiotics.
    Escano J; Stauffer B; Brennan J; Bullock M; Smith L
    Microbiologyopen; 2014 Dec; 3(6):961-72. PubMed ID: 25400246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-translational modifications during lantibiotic biosynthesis.
    Xie L; van der Donk WA
    Curr Opin Chem Biol; 2004 Oct; 8(5):498-507. PubMed ID: 15450492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pseudomycoicidin, a Class II Lantibiotic from Bacillus pseudomycoides.
    Basi-Chipalu S; Dischinger J; Josten M; Szekat C; Zweynert A; Sahl HG; Bierbaum G
    Appl Environ Microbiol; 2015 May; 81(10):3419-29. PubMed ID: 25769830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissecting reactions of nonlinear precursor peptide processing of the class III lanthipeptide curvopeptin.
    Jungmann NA; Krawczyk B; Tietzmann M; Ensle P; Süssmuth RD
    J Am Chem Soc; 2014 Oct; 136(43):15222-8. PubMed ID: 25291240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New developments in lantibiotic biosynthesis and mode of action.
    Patton GC; van der Donk WA
    Curr Opin Microbiol; 2005 Oct; 8(5):543-51. PubMed ID: 16118063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Posttranslationally modified bacteriocins--the lantibiotics.
    Guder A; Wiedemann I; Sahl HG
    Biopolymers; 2000; 55(1):62-73. PubMed ID: 10931442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lantibiotic engineering: molecular characterization and exploitation of lantibiotic-synthesizing enzymes for peptide engineering.
    Nagao J; Aso Y; Shioya K; Nakayama J; Sonomoto K
    J Mol Microbiol Biotechnol; 2007; 13(4):235-42. PubMed ID: 17827974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations in Dynamic Structural Elements Alter the Kinetics and Fidelity of the Multifunctional Class II Lanthipeptide Synthetase, HalM2.
    Uggowitzer KA; Habibi Y; Wei W; Moitessier N; Thibodeaux CJ
    Biochemistry; 2021 Feb; 60(5):412-430. PubMed ID: 33507068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure and dynamics of the lantibiotic mutacin 1140.
    Smith L; Zachariah C; Thirumoorthy R; Rocca J; Novák J; Hillman JD; Edison AS
    Biochemistry; 2003 Sep; 42(35):10372-84. PubMed ID: 12950164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bacillus subtilis antibiotics: structures, syntheses and specific functions.
    Stein T
    Mol Microbiol; 2005 May; 56(4):845-57. PubMed ID: 15853875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissecting the maturation steps of the lasso peptide microcin J25 in vitro.
    Yan KP; Li Y; Zirah S; Goulard C; Knappe TA; Marahiel MA; Rebuffat S
    Chembiochem; 2012 May; 13(7):1046-52. PubMed ID: 22488892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unique peptide modifications involved in the biosynthesis of lantibiotics.
    Jack RW; Sahl HG
    Trends Biotechnol; 1995 Jul; 13(7):269-78. PubMed ID: 7646850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lantibiotics: insight and foresight for new paradigm.
    Nagao J; Asaduzzaman SM; Aso Y; Okuda K; Nakayama J; Sonomoto K
    J Biosci Bioeng; 2006 Sep; 102(3):139-49. PubMed ID: 17046525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigations of the MceIJ-catalyzed posttranslational modification of the microcin E492 C-terminus: linkage of ribosomal and nonribosomal peptides to form "trojan horse" antibiotics.
    Nolan EM; Walsh CT
    Biochemistry; 2008 Sep; 47(35):9289-99. PubMed ID: 18690711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The biology of lantibiotics from the lacticin 481 group is coming of age.
    Dufour A; Hindré T; Haras D; Le Pennec JP
    FEMS Microbiol Rev; 2007 Mar; 31(2):134-67. PubMed ID: 17096664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosynthesis of aminovinyl-cysteine-containing peptides and its application in the production of potential drug candidates.
    Sit CS; Yoganathan S; Vederas JC
    Acc Chem Res; 2011 Apr; 44(4):261-8. PubMed ID: 21366289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.